Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 4/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorobenzene SCHEMBL27582642 | 0.88 | DPP4 (0.67) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5075830 | 0.85 | DPP4 (0.71) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL27600177 | 0.81 | DPP4 (0.67) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5642329 | 0.81 | DPP4 (0.67) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5073444 | 0.81 | DPP4 (0.72) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5718859 | 0.81 | L3MBTL1 (0.80) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5643215 | 0.81 | DPP4 (0.69) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL555190 | 0.81 | DPP4 (0.77) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5643920 | 0.81 | DPP4 (0.69) | KMT2AALDH1A1HTTDPP4L3MBTL1 | |
| SCHEMBL5639901 | 0.80 | DPP4 (0.63) | KMT2AALDH1A1HTTDPP4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415767-B1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | KMT2A 1732/4885ALDH1A1 445/4885HTT 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.